The Evolutionary Tale and Future Directions of Aromatase Inhibitors in Breast Carcinoma

Dipanjan Bhattacharjee, K. Meena Kumari, S. Avin, V. Amberkar Mohan Babu

Research output: Contribution to journalReview article

Abstract

Aromatase inhibitors have often been likened to that of 'medical scalpels' for the treatment of breast carcinoma. By inhibiting the singular step of aromatisation, they have proven to be extremely effective allies in the treatment of breast cancer among postmenopausal women. However, their relevance soon may not be limited to the post-menopausal age group alone. Recent studies have hinted at their utility amongst the premenopausal women; combined with ovarian ablation techniques, aromatase inhibitors may prove to be equally effective and more, as compared to tamoxifen in this age-group. Additionally, explorations aimed at ascertaining their potential utility as an effective preventive strategy against breast carcinoma have yielded encouraging results. However, for aromatase inhibitors to be able to attain their full potential, further strategic fine-tuning aimed at maximising their efficacy and minimising their potentially far-reaching adverse effects, is the need of the hour. Despite the recent diversification, the issue of resistance to aromatase inhibitors in breast cancer threatens to derail the advances so gained till date. Fortunately, a few novel ploys have come to the fore, for instance combining aromatase inhibitors with HER-2 antibodies that could potentially help circumvent the menace of resistance in the near future. Till date, the utility of aromatase inhibitors can at best be described as onedimensional. However, with the unearthing of potential new avenues for its application, this assortment of molecules today stands on the precipice of ushering in a new revolution in the treatment of breast carcinoma.

Original languageEnglish
Pages (from-to)1487-1499
Number of pages13
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume17
Issue number11
DOIs
Publication statusPublished - 24-11-2017

Fingerprint

Aromatase Inhibitors
Breast Neoplasms
Age Groups
Ablation Techniques
Tamoxifen
Direction compound
Therapeutics
Antibodies

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Cancer Research

Cite this

Bhattacharjee, Dipanjan ; Kumari, K. Meena ; Avin, S. ; Babu, V. Amberkar Mohan. / The Evolutionary Tale and Future Directions of Aromatase Inhibitors in Breast Carcinoma. In: Anti-Cancer Agents in Medicinal Chemistry. 2017 ; Vol. 17, No. 11. pp. 1487-1499.
@article{d7eb5973c2d44af08c8897b772da5c8b,
title = "The Evolutionary Tale and Future Directions of Aromatase Inhibitors in Breast Carcinoma",
abstract = "Aromatase inhibitors have often been likened to that of 'medical scalpels' for the treatment of breast carcinoma. By inhibiting the singular step of aromatisation, they have proven to be extremely effective allies in the treatment of breast cancer among postmenopausal women. However, their relevance soon may not be limited to the post-menopausal age group alone. Recent studies have hinted at their utility amongst the premenopausal women; combined with ovarian ablation techniques, aromatase inhibitors may prove to be equally effective and more, as compared to tamoxifen in this age-group. Additionally, explorations aimed at ascertaining their potential utility as an effective preventive strategy against breast carcinoma have yielded encouraging results. However, for aromatase inhibitors to be able to attain their full potential, further strategic fine-tuning aimed at maximising their efficacy and minimising their potentially far-reaching adverse effects, is the need of the hour. Despite the recent diversification, the issue of resistance to aromatase inhibitors in breast cancer threatens to derail the advances so gained till date. Fortunately, a few novel ploys have come to the fore, for instance combining aromatase inhibitors with HER-2 antibodies that could potentially help circumvent the menace of resistance in the near future. Till date, the utility of aromatase inhibitors can at best be described as onedimensional. However, with the unearthing of potential new avenues for its application, this assortment of molecules today stands on the precipice of ushering in a new revolution in the treatment of breast carcinoma.",
author = "Dipanjan Bhattacharjee and Kumari, {K. Meena} and S. Avin and Babu, {V. Amberkar Mohan}",
year = "2017",
month = "11",
day = "24",
doi = "10.2174/1871520617666170327114831",
language = "English",
volume = "17",
pages = "1487--1499",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

The Evolutionary Tale and Future Directions of Aromatase Inhibitors in Breast Carcinoma. / Bhattacharjee, Dipanjan; Kumari, K. Meena; Avin, S.; Babu, V. Amberkar Mohan.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 17, No. 11, 24.11.2017, p. 1487-1499.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The Evolutionary Tale and Future Directions of Aromatase Inhibitors in Breast Carcinoma

AU - Bhattacharjee, Dipanjan

AU - Kumari, K. Meena

AU - Avin, S.

AU - Babu, V. Amberkar Mohan

PY - 2017/11/24

Y1 - 2017/11/24

N2 - Aromatase inhibitors have often been likened to that of 'medical scalpels' for the treatment of breast carcinoma. By inhibiting the singular step of aromatisation, they have proven to be extremely effective allies in the treatment of breast cancer among postmenopausal women. However, their relevance soon may not be limited to the post-menopausal age group alone. Recent studies have hinted at their utility amongst the premenopausal women; combined with ovarian ablation techniques, aromatase inhibitors may prove to be equally effective and more, as compared to tamoxifen in this age-group. Additionally, explorations aimed at ascertaining their potential utility as an effective preventive strategy against breast carcinoma have yielded encouraging results. However, for aromatase inhibitors to be able to attain their full potential, further strategic fine-tuning aimed at maximising their efficacy and minimising their potentially far-reaching adverse effects, is the need of the hour. Despite the recent diversification, the issue of resistance to aromatase inhibitors in breast cancer threatens to derail the advances so gained till date. Fortunately, a few novel ploys have come to the fore, for instance combining aromatase inhibitors with HER-2 antibodies that could potentially help circumvent the menace of resistance in the near future. Till date, the utility of aromatase inhibitors can at best be described as onedimensional. However, with the unearthing of potential new avenues for its application, this assortment of molecules today stands on the precipice of ushering in a new revolution in the treatment of breast carcinoma.

AB - Aromatase inhibitors have often been likened to that of 'medical scalpels' for the treatment of breast carcinoma. By inhibiting the singular step of aromatisation, they have proven to be extremely effective allies in the treatment of breast cancer among postmenopausal women. However, their relevance soon may not be limited to the post-menopausal age group alone. Recent studies have hinted at their utility amongst the premenopausal women; combined with ovarian ablation techniques, aromatase inhibitors may prove to be equally effective and more, as compared to tamoxifen in this age-group. Additionally, explorations aimed at ascertaining their potential utility as an effective preventive strategy against breast carcinoma have yielded encouraging results. However, for aromatase inhibitors to be able to attain their full potential, further strategic fine-tuning aimed at maximising their efficacy and minimising their potentially far-reaching adverse effects, is the need of the hour. Despite the recent diversification, the issue of resistance to aromatase inhibitors in breast cancer threatens to derail the advances so gained till date. Fortunately, a few novel ploys have come to the fore, for instance combining aromatase inhibitors with HER-2 antibodies that could potentially help circumvent the menace of resistance in the near future. Till date, the utility of aromatase inhibitors can at best be described as onedimensional. However, with the unearthing of potential new avenues for its application, this assortment of molecules today stands on the precipice of ushering in a new revolution in the treatment of breast carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85038963860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038963860&partnerID=8YFLogxK

U2 - 10.2174/1871520617666170327114831

DO - 10.2174/1871520617666170327114831

M3 - Review article

C2 - 28356008

AN - SCOPUS:85038963860

VL - 17

SP - 1487

EP - 1499

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 11

ER -